HHS announced its new price transparency rules for direct-to-consumer TV ads. Now the industry has to sort out what to do about them.
Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?
Med Ad News asked its sources for the Agenda 2019 special feature which key questions for 2019 we’d left out. This is what they told us.
For the 11th year, Med Ad News selected new Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.
While other products are showing signs of growth, the fate of AbbVie is still in the hands of the iconic autoimmune drug.
With two potential $6 billion brands now at the top of the company’s portfolio, Bristol-Myers Squibb is officially through the lean times.
On the far side of the company’s brief but transformative adventure with Sovaldi and Harvoni, Gilead is returning to earth with a solid portfolio of HIV drugs.
With new products showing signs of impressive growth, Eli Lilly seems safely past the company’s recent patent trough.
Nine years ago Keytruda was about to be out-licensed. Now Keytruda is Merck’s top-selling medicine.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.